2006

Marketing Authorisation for our product FLUCANZOLE in UK

December 01, 2006

Medicines and Healthcare products Regulatory Authority has granted marketing Authorisations under The Medicines for Human Use (Marketing Authorisations etc.,) Regulations, for marketing of our product FLUCANAZOLE in United Kingdom.

FORBES rates FDC as "BEST UNDER A BILLION COMPANIES

November 14, 2006

Forbes Asia October 2006 issue has ranked FDC Ltd. as one of the 200 "Best under a Billion Companies" with sales of less than $1 billion with solid top and bottom line gains and potentials for more success.

FDC enters into an licensing agreement with gilead sciences inc, for manufacturing and distribution of generic versions of viread in the developing world

November 14, 2006

FDC has entered into a non-exclusive license agreement with GILEAD Sciences Inc., for production and distribution of Tenofovir Disoproxil Fumarate (tenofovir DF) to 95 low-income countries around the world, including India. Tenofovir DF is sold by Gilead under the brand name Viread (R). In addition, this agreement also allows the manufacture of commercial quantities of both active pharmaceutical ingredient (API) and finished product.

FDC LIMITED and AKORN INC, USA, sign exclusive development and Supply Agreement for Two Ophthalmic Suspensions drug Products.

November 14, 2006

FDC Limited and Akorn Inc., a leading marketing Company for Ophthalmic drugs in the United States, have signed an exclusive development and supply agreement for two Ophthalmic suspension drug products. The two drugs currently have a combined United States market size of approximately $170 million. Under the terms of the agreement, FDC will fund the development and be responsible for manufacturing the two Ophthalmic suspensions. Akorn will be responsible for marketing the two drugs in the United States and will receive 40% of the gross profit, while FDC will receive 60% of the gross profit generated from sales of the two drugs. FDC will own the ANDAs and Akorn has agreed to meet the annual minimum unit sales requirements in order to maintain United States marketing exclusivity.

Mr. Arthur S. Przbyl, President and CEO of Akorn has stated, "This Agreement further strengthens our increasing partnership with FDC. We remain impressed with FDC's blow- fill- seal technology and its use in ophthalmic products. We have filed two ANDAs this year for FDC and look forward to several more".

Mr. Nandan Chandavarkar, Jt. Managing Director of FDC, has stated "FDC is excited about working with Akorn on these suspension Products. We believe that our strong product development and manufacturing capabilities are very well complemented by Akron's strengths in sales and marketing."